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n	 INTRODUCTION
Fibromyalgia (FM) is a chronic pain syndrome that affects at least 2% of the 
adult population, and is characterised by 
widespread pain, fatigue, sleep alterations, 
and distress (1). It is currently defined as 
chronic widespread pain (CWP) with allo-
dynia or hyperalgesia to pressure pain, and 
classified as one of the large group of soft-
tissue pain syndromes (1-3). There is grow-
ing evidence that it may involve a central 
nervous system (CNS) malfunction that 
increases pain transmission and perception 
(4). The widespread nature of spontaneous 
pain in FM involves general mechanisms 
that may include the spinal or supraspinal 
modulation of normal peripheral input, or 
effector mechanisms that alter sensitivity 
to peripheral pain (4, 5). The etiology of 
FM is not completely understood and the 
syndrome is influenced by factors such as 
stress, medical illness, and a variety of pain 
conditions including trauma, infections 
(e.g., hepatitis C virus, HIV and Lyme dis-
ease), emotional stress, catastrophes (e.g., 
war), autoimmune diseases and other pain 
conditions (6-8). FM is often associated 
with other diseases that act as confound-
ing and aggravating factors, such as rheu-
matoid arthritis (RA), spondyloarthritides 
(SpA), osteoarthritis (OA) and thyroid dis-
ease (8). 
The aim of this review is to analyse the 
impact of FM in arthritides and their treat-
ment.
Pain as a symptom of FM and other rheu-
matic diseases
The most frequent and typical symptoms of 
FM are generalised pain, stiffness, fatigue, 
and poor sleep (9), but the defining symp-
tom is widespread chronic pain lasting at 
least three months, usually in all four limbs 
and the upper or lower back. The pain has 
been described in many ways (burning, 
searing, tingling, shooting, stabbing, deep-
ly aching, sharp, or “feeling bruised all 
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Fibromyalgia (FM) is a chronic pain syndrome that affects at least 2% of the adult population. It is characterised 
by widespread pain, fatigue, sleep alterations and distress, and emerging evidence suggests a central nervous 
system (CNS) malfunction that increases pain transmission and perception. FM is often associated with other 
diseases that act as confounding and aggravating factors, such as rheumatoid arthritis (RA), spondyloarthritides 
(SpA), osteoarthritis (OA) and thyroid disease. Mechanism-based FM management should consider both pe-
ripheral and central pain, including effects due to cerebral input and that come from the descending inhibitory 
pathways. Rheumatologists should be able to distinguish primary and secondary FM, and need new guidelines 
and instruments to avoid making mistakes, bearing in mind that the diffuse pain of arthritides compromises the 
patients’ quality of life.
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over”) and, like stiffness, it is often wors-
ened by cold or damp weather, anxiety or 
stress, excessive or too little physical activ-
ity, poor sleep, and noise (1, 9). About 65% 
of the patients say they “hurt all over”, and 
this may be useful in differentiating FM 
from other conditions (8, 9). 
However, musculoskeletal pain is com-
mon in patients with rheumatic diseases, 
and it is not always easy to discover its 
cause. Pain is certainly the cornerstone of 
a diagnosis of FM, but it is accompanied 
an array of multi-system symptoms that are 
common to various musculoskeletal condi-
tions (such as fatigue, Raynaud’s phenom-
enon, sleep disturbances, muscle stiffness, 
sicca syndrome, irritable bowel disease, 
depression and anxiety), and the absence 
of specific laboratory findings can easily 
lead to a misdiagnosis (9, 10). As FM-like 
symptoms are frequently encountered, dif-
ferential diagnoses against other causes of 
chronic pain are essential (8). When the 
pain involves a large number of joints, it 
may be confused with the widespread pain 
of FM, but the degree of pain measured by 
means of a visual analogue scale (VAS) is 
not helpful in distinguishing FM from con-
ditions such as RA or OA (11, 12). Further-
more, as it can co-exist with other immu-
no-inflammatory diseases, many rheumatic 
and non-rheumatic diseases can easily be 
misdiagnosed as FM (12). There are no in-
strumental tests to confirm the diagnosis, 
but many of the differential diagnoses can 
be excluded by means of an extensive clini-
cal examination and patient history. 
One study (13) of inaccurate diagnoses 
of FM in a cohort of patients referred to 
a rheumatology clinic found that FM was 
confirmed in only 34% of the patients 
presenting with musculoskeletal pain. 
The symptoms distinguishing FM and 
non-FM patients were tender points (TPs) 
(P<0.0001) and fatigue (P=0.0003), where-
as prolonged early morning stiffness clini-
cally distinguished non-FM patients, al-
though it was also found in 25% of the FM 
patients. Given the large number of misdi-
agnoses (66%), the authors concluded that 
a wider range of diseases should be consid-
ered when making a differential diagnosis.
Di Franco et al. (14) studied 427 outpa-
tients, 57 of whom had been previously 
misdiagnosed as having other muscu-
loskeletal disorders (the MSD group); the 
others had been previously correctly di-
agnosed as having FM or were diagnosed 
as having it during the course of the study. 
The FM and MSD groups were compara-
ble in terms of demographic data and re-
ferral patterns, but the patients with MSD 
had significantly more frequent antinuclear 
antibodies (ANA) and low titres of rheu-
matoid factor (RF) positivity. Moreover, 
there were significant differences in the 
use of non-steroidal anti-inflammatory 
drugs (NSAIDs), steroids, DMARDs and 
biological agents (P<0.0001 for each class 
of drugs) between the two groups (14). The 
authors concluded that, as FM symptoms 
generally respond poorly to various treat-
ments, the consequences of a misdiagnosis 
and mistreatment are a later diagnosis and 
a longer disease duration, which can wors-
en the patients’ quality of life and increase 
the economic burden on society.
Many differential diagnoses can be ex-
cluded by an extensive clinical examina-
tion and patient history but, given the con-
sidering overlap of FM with other medical 
conditions, treating physicians need to 
remain alert. Chest X-ray and abdominal 
ultrasonography are the first steps in the 
general assessment of all the patients with 
suspected FM (10), but establishing a diag-
nosis may be difficult because of the multi-
faceted nature of the syndrome.
Fibromyalgia and rheumatoid arthritis 
FM may occur alone (primary FM) or in 
combination with other diseases (second-
ary FM): 25% of FM patients have RA, and 
a recent study estimated that the incidence 
of new-onset FM in RA patients was 20% 
(15). In the same study, 7.4% of the RA 
patients satisfied the criteria for FM at the 
time of the last observation, and 19.8% sat-
isfied them at some time during the follow-
up, with a similar incidence in men (7.0%) 
and women (8.1%). The factors that corre-
lated with developing FM in RA included 
social disadvantage, psychological distress, 
comorbidities, and the severity of the RA. 
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RA is a complex inflammatory arthritis 
whose activity cannot be assessed using a 
single physical or laboratory measure (16). 
In 1993, the Disease Activity Score (DAS) 
was developed to provide a quantifiable 
composite measure of RA disease activity 
(16-18). It was based on a combination of 
swollen and tender joint counts, the acute-
phase response and general health, and the 
use of statistical measures that included dis-
criminant and multiple regression analysis. 
It has been found that the has more power 
than other indices or single variables in dis-
criminating low from high levels of disease 
activity, and the area under the curve of C-
reactive protein (CRP) correlates well with 
joint damage over time (19). 
DAS28 is a modified version of the origi-
nal DAS that is based on the same four 
variables, but uses swollen and tender joint 
counts of only 28 joints: it is a continuous 
index ranging from 0 to 9.4, in which low 
disease activity is defined as a score of 
≤3.2, moderate disease activity is defined 
as a score of >3.2 and ≤5.1, and high dis-
ease activity is defined as a score of >5.1 
(20). A commonly used cut-off point for 
remission is <2.6 (17, 18, 20). During the 
current decade, rheumatologists have wit-
nessed a series of major developments in 
the treatment of RA, including new treat-
ments that make it possible to aim at strin-
gent targets, including remission. Outcome 
assessments have also been improved and 
become easier to use in clinical practice, 
thus allowing the assessment of disease 
activity and response to treatment, and the 
categorisation of disease activity states. 
Patients with RA should undergo a careful 
clinical examination in order to evaluate 
the clinical association with FM, optimise 
therapy, reduce healthcare costs. Pain, fa-
tigue and stiffness are common in RA, and 
FM plays a major role (9, 16). Wolfe and 
Michaud (21) found that 17% of their RA 
patients had FM, and that their RA was 
more subjectively and objectively severe. 
Another very interesting study found that 
patients with RA and concomitant FM had 
significantly greater disease activity as 
measured by DAS28, but the patients with 
RA alone showed significantly more severe 
joint destruction. One study on 120 RA 
patients (including 25 with concomitant 
FM) found significantly higher tender joint 
counts (TJC) and global health VAS values, 
the subjective measurements that contrib-
ute most to the differences in disease ac-
tivity in RA patients with and without FM; 
however, the doctor’s global heath VAS 
values incorporated in a simple disease ac-
tivity index (SDAI) and a clinical disease 
activity index (CDAI) were also markedly 
higher in the patients with both diseases 
(22). Composite indices such as DAS28, 
SDAI and CDAI are widely used in every-
day clinical practice and clinical trials, but 
they may be insufficient to evaluate real in-
flammatory activity in cases of RA associ-
ated with a chronic pain syndrome such as 
FM; rheumatologists need to be aware of 
these limitations. 
Ultrasonography (US) can identify the el-
ements characteristic of RA or FM, and 
therefore help clinicians to make a correct 
diagnosis (23). An examination performed 
by an expert US rheumatologist using the 
newer colour Doppler US and the spectral 
Doppler Resistivity Index, can differenti-
ate inflammatory and non-inflammatory 
disease and be used as an indicator of RA. 
Meenagh et al. (24) have shown that the 
majority of FM patients have no significant 
pathological US abnormalities.
Fibromyalgia and spondyloathropathies 
Spondyloarthropathies (SpA) are a group 
of inflammatory arthritides consisting of 
ankylosing spondylitis (AS), reactive ar-
thritis, arthritis/spondylitis associated with 
psoriasis (PsA), and arthritis/spondylitis 
associated with inflammatory bowel dis-
eases, all of which have sometimes been 
found to be associated with FM.
Fibromyalgia and psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic in-
flammatory arthropathy of unknown eti-
ology that is associated with psoriasis. It 
occurs in up to one-third of patients with 
psoriasis and has a heterogeneous pat-
tern expressed by various manifestations 
including mono-oligoarthritis (an erosive 
and destructive polyarthritis indistinguish-
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able from RA) and spondyloarthropathy 
with axial involvement or enthesitis (25). 
The prevalence of FM in PsA patients is 
unknown, although one study found ten-
derness in ten or more fibrotic sites in 24% 
of patients with PsA and 57% of RA pa-
tients (26). If there are no objective signs 
of inflammation at entheseal sites, it can be 
difficult to distinguish enthesitic and fibro-
myalgic pain clinically because the symp-
toms and signs may be aspecific and rela-
tively indistinguishable from those of FM. 
In a cross-sectional study involving 266 pa-
tients with PsA and 120 patients with FM 
by Marchesoni et al. (26), univariate analy-
sis showed that the latter had higher mean 
tender point and enthesitis scores, more 
somatic symptoms, and responded less to 
NSAIDs. Multivariate analysis showed that 
the presence of ≥6 FM-associated symp-
toms and ≥8 tender points was the best pre-
dictor of FM. The authors concluded that 
PsA and FM share clinical features, and 
that the number of FM-associated symp-
toms and tender point count were the most 
useful variables for discriminating FM.
As in patients with RA, US permits the 
early detection and characterisation of the 
inflammatory process in different tissues in 
PsA patients, and helps in the differential 
diagnosis.
Fibromyalgia and ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic 
inflammatory disease that affects the axial 
skeletal system, causing pain and func-
tional incapacity (28, 29). To measure the 
impact of AS on a patient’s life, question-
naires are used to assess disease activity 
(BASDAI), functional incapacity (BASFI), 
and the quality of life (ASQoL). The im-
pact of FM can be assessed using the Fi-
bromyalgia Impact Questionnaire (FIQ) 
(30), but only some studies have demon-
strated correlations between FM and AS.
Aloush et al. (31) studied 36 patients with 
AS (18 males and 18 females) and diag-
nosed FM in 50% of the women but none 
of the men. They pointed out that patients 
with two concomitant diseases were more 
functionally impaired, which led to high-
er BASDAI and BASFI scores than those 
of patients with only one disease. In an-
other study of 71 patients, the prevalence 
of FM was 15% (45.5% males and 54.5% 
females): these patients had significantly 
higher BASDAI scores (P<0.001 at Stu-
dent’s t-test and P=0.002940 at Wilcoxon’s 
test), BASFI scores (P<0.001 at Student’s 
t-test and P=0.001992 at Wilcoxon’s test), 
and ASQoL scores (P=0.0019 at Student’s 
t-test and P=0.001884 at Wilcoxon’s test) 
(32). A cross-sectional Spanish study of 
462 patients with definite AS found that the 
prevalence of FM was 4.11% in the popu-
lation as a whole, but 10.83% among the 
women (33). The BASDAI, BASFI and to-
tal Bath AS radiology index (BASRI) were 
strongly influenced by the presence of FM 
and, when the authors used the inverse re-
lationship between BASDAI or BASFI and 
total BASRI to make a ratio, they found 
that the patients with a BASDAI/BASRI 
ratio of ≥1.5 or a BASFI/BASRI ratio of 
≥1.08 were very likely to have FM. They 
concluded that FM distorts the measures of 
activity and functional damage in patients 
with AS, and that the BASDAI/BASRI and 
BASFI/BASRI ratios are a useful means 
of identifying such patients and avoiding 
over-treatment (33).
The diagnosis of AS is based on the pres-
ence of chronic vertebral pain associated 
with morning stiffness, both of which are 
frequent in FM patients (29). Anxiety, de-
pression, fatigue, and sleep disorders, all of 
which are closely associated with pain, are 
significant in FM and very frequently re-
ported by patients with AS.
The current indication for the use of biolog-
ical agents in AS is generally based on the 
activity index but, before biological agents 
are prescribed, we suggest that the possible 
presence of concomitant FM should be in-
vestigated and the positive patients should 
be adequately treated and reassessed. AS 
can also easily be mistaken for FM because 
both occur in young patients who may have 
constitutional symptoms such as malaise, 
fatigue and impaired sleep (34). However, 
the hallmark of AS is sacroiliitis, which 
can be identified early by means of mag-
netic resonance imaging (MRI) (35) and is 
not found in patients with FM.
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Fibromyalgia and osteoarthritis 
Patients with OA and FM have more prob-
lems sleeping (70%) that correlate with 
fatigue (36), and are also associated with 
more severe OA and depression.
Bican et al. (37) compared 59 OA patients 
(90 knees) with FM who underwent prima-
ry total knee arthroplasty (TKA) with FM-
free control patients undergoing the same 
surgery. The FM patients had lower pre- 
and postoperative SF-36 scores and, after 
3.4 years of follow-up, were less satisfied 
with their TKA. However, their post-surgi-
cal improvement was comparable with that 
of the controls. FM should not be consid-
ered a contraindication for surgery.
The implications of concomitant FM in 
chronic diseases 
The multiple and complex mechanisms un-
derlying FM (38) include some that involve 
temporal summation (wind-up), long-term 
potentiation (LTP), heterosynaptic poten-
tiation, dysfunctional descending pain in-
hibition, and activation of the descending 
facilitatory pathway (38). Although pain 
in RA is often thought of as inflammatory 
and peripheral (4), central pain may also be 
important. Patients with RA have general 
hyperalgesia to mechanical and thermal 
stimuli in various body areas, not just at 
the sites of their inflamed joints (39). They 
also have enhanced pain reactivity as re-
flected by serum TNF levels. Wendler et al. 
(40) used electroencephalography to show 
that, in comparison with age- and gender-
matched controls, RA patients have greater 
cortical responses to repeated noxious 
stimulation, thus suggesting changes in the 
CNS modulation of pain. Moreover, it has 
been shown that the relationships between 
inflammation, psychosocial factors, and 
peripheral and central pain processing are 
intricately inter-related not only in patients 
with RA (41), but also in those with OA. 
One small study has suggested that OA pa-
tients also have widespread hyperalgesia to 
mechanical or heat stimuli (42), and Kosek 
and Ordeberg found that patients with hip 
OA showed reduced descending analgesic 
activity, which partially normalised after 
hip arthroplasty, thus suggesting that the 
central factors were at least partially be-
ing driven by peripheral pain factors (43). 
Furthermore, randomised controlled trials 
have demonstrated that compounds that al-
ter pain neurotransmitters centrally, such as 
serotonin and norepinephrine (eg, duloxe-
tine, tricyclic antidepressants), are effica-
cious in OA (44).
Given these findings, the most important 
implication of concomitant FM in patients 
with chronic structural diseases is to rec-
ognise its presence in order to ensure op-
timal management (45). For example, FM 
symptoms with multiple tender points in 
patients with RA should not be automati-
cally attributed to increased RA activity, 
and the patients should not be prescribed 
higher doses of a biological agent or cor-
ticosteroids without an appropriate TP ex-
amination and laboratory evaluation (45). 
Attention should be given to managing the 
FM by means of centrally acting medica-
tions, cognitive behavioural therapy, and 
sleep management. An OA patient with 
severe pain will require analgesics that act 
both peripherally and centrally, such as cy-
clobenzaprine, pregabalin, duloxetine, or 
milnacipran (45).
A number of different pharmacologi-
cal treatments, including antidepressants, 
NSAIDS, opioids, sedatives, muscle relax-
ants and anti-epileptic agents, have been 
used to treat FM with varying results (46). 
Moreover, physical exercise and multimo-
dal cognitive behavioural therapy seem to 
be the most widely accepted and benefi-
cial forms of non-pharmacological therapy 
(47). Given that no single treatment for 
pain is ideal, a multimodal approach is rec-
ommended. 
n	 CONCLUSIONS
The presence of diffuse pain in arthritides 
does not increase overall mortality but 
compromises the patients’ quality of life. 
Mechanism-based management should 
consider both peripheral and central pain, 
including the effects due to cerebral input 
and from the descending inhibitory path-
ways. Optimal therapy should take into 
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account symptoms such as fatigue, mood, 
sleep, and the overall quality of life. Rheu-
matologists should be able to recognise and 
distinguish primary and secondary FM, 
and need new guidelines and instruments 
to avoid making mistakes.
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